Ke Gao
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ke Gao has a total of 42 co-authors. Here are the top co-authors by number of shared publications:
- Shu Zhang
Liver Cancer Institute, Zhongshan Hospital, Key Laboratory of Carcinogenesis and Cancer Invasion (Ministry of Education), Fudan University, Shanghai, China
3 shared publications Jieyi Shi
2 shared publications- Bing Bai
Department of Laboratory Medicine, Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Medical School of Nanjing University, Nanjing, China
1 shared publication - Chen Huang
Department of Gastrointestinal Surgery, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200080, China.
1 shared publication Cun Wang
1 shared publication- Dongning Rao
Department of Hepatobiliary Surgery and Transplantation, Liver Cancer Institute, Zhongshan Hospital, Fudan University, Key Laboratory of Carcinogenesis and Cancer Invasion of Ministry of Education, Shanghai, 200032, China
1 shared publication
Latest Publications
- Open Access
- 5 October 2026
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 25 (11)
SLC35A3 Remodels Site-Specific N-Glycosylation and Defines a Druggable Glycosylation Target in Hepatocellular Carcinoma
- 5 October 2026
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 25 (11)
Open AccessSLC35A3 Remodels Site-Specific N-Glycosylation and Defines a Druggable Glycosylation Target in Hepatocellular Carcinoma
- 6 August 2024
- Published by Elsevier in Analytica Chimica Acta
- Vol. 1322, 343066
Benchmark N-glycoproteomics study of common differential tissue and serum N-glycoproteins of patients with hepatocellular carcinoma
- 6 August 2024
- Published by Elsevier in Analytica Chimica Acta
- Vol. 1322, 343066
Benchmark N-glycoproteomics study of common differential tissue and serum N-glycoproteins of patients with hepatocellular carcinoma
- Open Access
- 27 July 2024
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 23 (9) , 100821
ST3GAL1 Promotes Malignant Phenotypes in Intrahepatic Cholangiocarcinoma
- 27 July 2024
- Published by Elsevier in Molecular & Cellular Proteomics
- Vol. 23 (9) , 100821
Open AccessST3GAL1 Promotes Malignant Phenotypes in Intrahepatic Cholangiocarcinoma
- Top Cited Papers
- 3 May 2024
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 384 (6695) , eadj4857
A blueprint for tumor-infiltrating B cells across human cancers
B lymphocytes are essential mediators of humoral immunity and play multiple roles in human cancer. To decode the functions of tumor-infiltrating B cells, we generated a B cell blueprint encompassing single-cell transcriptome, B cell–receptor repertoire, and chromatin accessibility data across 20 different cancer types (477 samples, 269 patients). B cells harbored extraordinary heterogeneity and comprised 15 subsets, which could be grouped into two independent developmental paths (extrafollicular versus germinal center). Tumor types grouped into the extrafollicular pathway were linked with worse clinical outcomes and resistance to immunotherapy. The dysfunctional extrafollicular program was associated with glutamine-derived metabolites through epigenetic-metabolic cross-talk, which promoted a T cell–driven immunosuppressive program. These data suggest an intratumor B cell balance between extrafollicular and germinal-center responses and suggest that humoral immunity could possibly be harnessed for B cell–targeting immunotherapy.
- 3 May 2024
- Published by American Association for the Advancement of Science (AAAS) in Science
- Vol. 384 (6695) , eadj4857
Top Cited PapersA blueprint for tumor-infiltrating B cells across human cancers
B lymphocytes are essential mediators of humoral immunity and play multiple roles in human cancer. To decode the functions of tumor-infiltrating B cells, we generated a B cell blueprint encompassing single-cell transcriptome, B cell–receptor repertoire, and chromatin accessibility data across 20 different cancer types (477 samples, 269 patients). B cells harbored extraordinary heterogeneity and comprised 15 subsets, which could be grouped into two independent developmental paths (extrafollicular versus germinal center). Tumor types grouped into the extrafollicular pathway were linked with worse clinical outcomes and resistance to immunotherapy. The dysfunctional extrafollicular program was associated with glutamine-derived metabolites through epigenetic-metabolic cross-talk, which promoted a T cell–driven immunosuppressive program. These data suggest an intratumor B cell balance between extrafollicular and germinal-center responses and suggest that humoral immunity could possibly be harnessed for B cell–targeting immunotherapy.